✦ LIBER ✦

Benefits of a New, Nonsystemic Lipid-Lowering Agent: The Clinician's Perspective

✍ Scribed by Michael H. Davidson; Mary R. Dicklin; Kevin C. Maki; Ruth M. Kleinpell

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Limits of lipid-lowering therapy: the po

✍ D.M Kramsch 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 55 KB

S46 The clinical benefits of aggressive

✍ John A. Farmer 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 179 KB

Policosanol: Clinical pharmacology and t

✍ Ioanna Gouni-Berthold; Heiner K. Berthold 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Inhibition of low-density lipoprotein (L

✍ R Menéndez; R Más; A.M Amor; R.M González; J.C Fernández; I Rodeiro; M Zayas; S 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Efficacy and benefits of lipid-lowering

✍ Guy De Backer 📂 Article 📅 2010 🏛 Elsevier Science 🌐 Spanish ⚖ 166 KB

Gemfibrozil — The effect on biliary chol

✍ M.J. Hall; L.M. Nelson; R.I. Russell; A.N. Howard 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 452 KB